Your breast cancer news round-up for March
Every month we gather recent highlights in breast cancer research, new treatment developments, and the latest industry news. Here’s your update for March 2024.
Breast cancer research round-up
Insights into fulvestrant resistance revealed: A study published in Cancer Discovery reveals why some advanced ER+ breast cancers become resistant to the ER degrader drug fulvestrant. The team from the Institute for Cancer Research in London also identified drugs currently in development which could provide an alternative treatment.?
Fall in breast cancer deaths: A multi-centre study from Stanford Medicine reveals a 58% decline in breast cancer-related deaths in the US from 1975 to 2019. Writing in JAMA, the researchers attribute this significant drop to the combined impact of screening and advancements in treatment.
Breast cancer in the news
Improvements in survival slowing down: A report from Cancer Research UK says that, although cancer survival rates continue to improve, the rate of progress was significantly faster in the 2000s than it was in the 2010s. The charity claims this slow-down is largely caused by reduced investment in research to improve prevention, diagnosis, and treatment.
Transforming clinical trials for women: An article published in Clinical Leader sets out five ways clinical trials could be changed to bridge gaps in our knowledge and better serve women. They include: representing the voices of women in trial design; using data to reduce racial disparities; and investing in new ways to understand how current drugs affect women.
领英推荐
What is Cerca Biotech up to?
Help improve diagnosis of HER2-low breast cancers: One of our key goals for clinical validation in 2024 is to demonstrate that MammaTyper? is a more reliable way to define HER2-low status. On our blog, we set out the studies we hope to conduct in this area. If you are interested in collaborating with us to help improve diagnosis and treatment of HER2-low breast cancer, please get in touch: [email protected]?
EBCC, Milan: We’ll be attending the 14th European Breast Cancer Conference (EBCC) in Milan, Italy. We are pleased to have a booth in the Exhibition Hall, as well as several posters featuring MammaTyper? data.
Additionally, we are hosting an exclusive evening event on Thursday 21st March. This is a closed event with very limited places? for those interested in networking and finding out more about MammaTyper? in clinical practice, with leading experts from around the world.
If you’ll be attending the EBCC and want to meet for a chat, get in touch at: [email protected]?